These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 15547201)

  • 1. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response evaluation of gastrointestinal stromal tumors.
    Choi H
    Oncologist; 2008; 13 Suppl 2():4-7. PubMed ID: 18434631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
    Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD
    AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate.
    Erturk SM
    AJR Am J Roentgenol; 2005 Nov; 185(5):1366; author reply 1366-7. PubMed ID: 16247167
    [No Abstract]   [Full Text] [Related]  

  • 10. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA; Nair N
    Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
    Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
    Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
    Zincirkeser S; Sevinc A; Kalender ME; Camci C
    World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
    Van den Abbeele AD
    Oncologist; 2008; 13 Suppl 2():8-13. PubMed ID: 18434632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors].
    García-González J; Sánchez Salmón A; Areses Manrique C; León Mateos L; Barandela Salgado J; López López R
    Rev Esp Med Nucl; 2007; 26(2):100-2. PubMed ID: 17386236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
    Otomi Y; Otsuka H; Morita N; Terazawa K; Furutani K; Harada M; Nishitani H
    J Med Invest; 2010 Aug; 57(3-4):270-4. PubMed ID: 20847527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL; Gietema JA; van der Graaf WT
    Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Shinto A; Nair N; Dutt A; Baghel NS
    Clin Nucl Med; 2008 Jul; 33(7):486-7. PubMed ID: 18580237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
    Delgado Bolton RC; Ortega Candil A; Pérez Castejón MJ; Garcerant M; Cabrera Martín MN; Lapeña Gutiérrez L; Carreras Delgado JL
    Rev Esp Med Nucl; 2008; 27(2):112-7. PubMed ID: 18367049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
    Mabille M; Vanel D; Albiter M; Le Cesne A; Bonvalot S; Le Péchoux C; Terrier P; Shapeero LG; Dromain C
    Eur J Radiol; 2009 Feb; 69(2):204-8. PubMed ID: 19046841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.